Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)

Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-01 DOI:10.1016/j.ctarc.2025.100912

Davor Galusic , Josip Batinic , Ivan Krecak , Barbara Dreta , Delfa Radic Kristo , Mario Pirsic , Goran Rincic , Jasminka Sincic-Petricevic , Toni Valkovic , Milan Vujcic , Marin Simunic , Karla Misura Jakobac , Martina Sedinic Lacko , Klara Brcic , Vlatka Perisa , Fran Petricevic , Dragana Grohovac , Hrvoje Holik , Martina Moric Peric , Ivan Zekanovic , Sandra Basic-Kinda

{"title":"Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","authors":"Davor Galusic , Josip Batinic , Ivan Krecak , Barbara Dreta , Delfa Radic Kristo , Mario Pirsic , Goran Rincic , Jasminka Sincic-Petricevic , Toni Valkovic , Milan Vujcic , Marin Simunic , Karla Misura Jakobac , Martina Sedinic Lacko , Klara Brcic , Vlatka Perisa , Fran Petricevic , Dragana Grohovac , Hrvoje Holik , Martina Moric Peric , Ivan Zekanovic , Sandra Basic-Kinda","doi":"10.1016/j.ctarc.2025.100912","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles of carfilzomib are well-established in several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our real-world experience with carfilzomib-based regimens for treatment of patients with RRMM in Croatia.</div></div><div><h3>Methods</h3><div>Data on patients with RRMM starting carfilzomib-based protocols in the period between June 2019 and February 2023 was collected by retrospective chart review from 14 Croatian centres.</div></div><div><h3>Results</h3><div>A total of 119 patients with RRMM were included; median age was 66 years (range 45–83 years), 59 (49.6 %) were females, and the median number of previous lines of therapies was 2 (range 1–8). Triplet based regimen was treatment choice in 84 (70.6 %) and 35 (29.4 %) patients were treated with carfilzomib in combination with dexamethasone (Kd). Overall response rate was 61.7 %, with 20 patients (18.7 %) achieving complete response (CR). Median progression free survival (PFS) and overall survival (OS) for entire cohort were 9.4 and 13.2 months, respectively. Median PFS was 12.8 months and 4.1 months for the triplets and doublets, respectively; the corresponding median OS was 18.6 and 7.9 months, respectively. The most common adverse events were anemia and thrombocytopenia; 19 patients (16 %) experienced cardiovascular events.</div></div><div><h3>Conclusion</h3><div>This is the first study to analyze clinical outcomes of RRMM patients treated with carfilzomib-based regimens in Croatia. Carfilzomib-based regimens showed substantial efficacy and acceptable toxicity in RRMM, especially in earlier treatment lines and triplet combinations.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100912"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles of carfilzomib are well-established in several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our real-world experience with carfilzomib-based regimens for treatment of patients with RRMM in Croatia.

Methods

Data on patients with RRMM starting carfilzomib-based protocols in the period between June 2019 and February 2023 was collected by retrospective chart review from 14 Croatian centres.

Results

A total of 119 patients with RRMM were included; median age was 66 years (range 45–83 years), 59 (49.6 %) were females, and the median number of previous lines of therapies was 2 (range 1–8). Triplet based regimen was treatment choice in 84 (70.6 %) and 35 (29.4 %) patients were treated with carfilzomib in combination with dexamethasone (Kd). Overall response rate was 61.7 %, with 20 patients (18.7 %) achieving complete response (CR). Median progression free survival (PFS) and overall survival (OS) for entire cohort were 9.4 and 13.2 months, respectively. Median PFS was 12.8 months and 4.1 months for the triplets and doublets, respectively; the corresponding median OS was 18.6 and 7.9 months, respectively. The most common adverse events were anemia and thrombocytopenia; 19 patients (16 %) experienced cardiovascular events.

Conclusion

This is the first study to analyze clinical outcomes of RRMM patients treated with carfilzomib-based regimens in Croatia. Carfilzomib-based regimens showed substantial efficacy and acceptable toxicity in RRMM, especially in earlier treatment lines and triplet combinations.

查看原文本刊更多论文

卡非佐米在复发/难治性多发性骨髓瘤患者中的应用——真实世界的证据——克罗地亚血液病合作小组（KROHEM）的经验

背景以卡非佐米为基础的治疗方案大大改善了复发性/难治性多发性骨髓瘤（RRMM）的治疗。尽管卡非佐米的疗效和安全性已在多项临床试验中得到证实，但基于卡非佐米方案的真实世界数据却十分有限。在此，我们介绍克罗地亚RRMM患者使用卡非佐米方案治疗的实际经验。方法通过回顾性病历审查收集了2019年6月至2023年2月期间开始使用卡非佐米方案的RRMM患者数据，数据来自14个克罗地亚中心。结果共纳入119例RRMM患者；中位年龄为66岁（范围为45-83岁），59例（49.6%）为女性，既往治疗次数的中位数为2次（范围为1-8次）。84名患者（70.6%）选择了三联疗法，35名患者（29.4%）选择了卡非佐米联合地塞米松（Kd）疗法。总反应率为61.7%，其中20名患者（18.7%）获得完全反应（CR）。整个队列的中位无进展生存期（PFS）和总生存期（OS）分别为9.4个月和13.2个月。三联疗法和双联疗法的中位无进展生存期分别为12.8个月和4.1个月；相应的中位总生存期分别为18.6个月和7.9个月。最常见的不良反应是贫血和血小板减少；19 名患者（16%）发生了心血管事件。以卡非佐米为基础的治疗方案对RRMM显示出显著疗效和可接受的毒性，尤其是在早期治疗线和三联疗法中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.